TargetMol

Liafensine

Product Code:
 
TAR-T32737
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T32737-1mg1mg£381.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T32737-5mg5mg£812.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T32737-10mg10mg£1,083.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T32737-25mg25mg£1,572.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T32737-50mg50mg£2,095.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Liafensine( BMS-820836) is an inhibitor of serotonin-norepinephrine-dopamine reuptake (SNDRI).
CAS:
1198790-53-2
Formula:
C24H22N4
Molecular Weight:
366.468
Pathway:
GPCR/G Protein|Neuroscience
Purity:
0.98
SMILES:
CN1C[C@@H](c2ccc3ccccc3c2)c2ccc(cc2C1)-c1ccc(N)nn1
Target:
5-HT Receptor|Norepinephrine|Dopamine Receptor

Documents

References

1. Bhagwagar Z, Torbeyns A, Hennicken D, Zheng M, Dunlop BW, Mathew SJ, Khan A, Weisler R, Nelson C, Shelton R, Thase ME, Lane R. Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies. J Clin Psychopharmacol. 2015 Aug;35(4):454-9. doi: 10.1097/JCP.0000000000000335. PubMed PMID: 25961781. 2. Zheng M, Burt D, Chan W, Hawthorne D, Gasior M, Bhagwagar Z, Keswani S, AbuTarif M, Bertz R. Comparison of different QT interval correction methods for heart rate and QT beat-to-beat method in a thorough QT study of triple monoamine reuptake inhibitor BMS-820836. J Clin Pharmacol. 2015 Oct;55(10):1137-46. doi: 10.1002/jcph.528. Epub 2015 Jun 9. PubMed PMID: 25904041. 3. Zheng M, Appel L, Luo F, Lane R, Burt D, Risinger R, Antoni G, Cahir M, Keswani S, Hayes W, Bhagwagar Z. Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836. Psychopharmacology (Berl). 2015 Feb;232(3):529-40. doi: 10.1007/s00213-014-3688-x. Epub 2014 Aug 14. PubMed PMID: 25116481. 4. Risinger R, Bhagwagar Z, Luo F, Cahir M, Miler L, Mendonza AE, Meyer JH, Zheng M, Hayes W. Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. Psychopharmacology (Berl). 2014 Jun;231(11):2299-310. doi: 10.1007/s00213-013-3391-3. Epub 2013 Dec 15. PubMed PMID: 24337079.